A research team from Mannheim, Göttingen, Varna, and Princeton has discovered in animal studies with mice that the growth factor recombinant human erythropoietin (rhEPO) can significantly improve cognitive and social problems in Primrose syndrome. Primrose syndrome is a very rare and severe disease caused by changes in the ZBTB20 control gene. The study, which has now been published in JCI Insight, provides the first evidence that an already approved drug could counteract the severe neurological symptoms of this rare disease.
This article was originally published on MedicalXpress.com
